Mary Wilson
Well-known member
Published online July 26, 2021.
doi:10.1001/jamainternmed.2021.3779
Matthew S. Krantz, MD[SUP]1[/SUP]; Jason H. Kwah, MD, MSCI[SUP]2[/SUP]; Cosby A. Stone Jr, MD, MPH[SUP]1[/SUP]; et al
Allergic reactions after messenger RNA (mRNA) COVID-19 vaccines have been reported to be as high as 2%, with anaphylaxis occurring in up to 2.5 per 10 000 individuals.[SUP]1[/SUP] There is uncertainty as to whether to administer a second dose of mRNA COVID-19 vaccine after a first-dose reaction.[SUP]2[/SUP][SUP],3[/SUP] In this study, we examine the safety of the second dose of Pfizer-BioNTech or Moderna vaccine in those with a history of immediate and potentially allergic reactions to the first dose.
https://jamanetwork.com/journals/ja...m=social&utm_term=072621#.YP7U0j6Ma-8.twitter
doi:10.1001/jamainternmed.2021.3779
Matthew S. Krantz, MD[SUP]1[/SUP]; Jason H. Kwah, MD, MSCI[SUP]2[/SUP]; Cosby A. Stone Jr, MD, MPH[SUP]1[/SUP]; et al
Allergic reactions after messenger RNA (mRNA) COVID-19 vaccines have been reported to be as high as 2%, with anaphylaxis occurring in up to 2.5 per 10 000 individuals.[SUP]1[/SUP] There is uncertainty as to whether to administer a second dose of mRNA COVID-19 vaccine after a first-dose reaction.[SUP]2[/SUP][SUP],3[/SUP] In this study, we examine the safety of the second dose of Pfizer-BioNTech or Moderna vaccine in those with a history of immediate and potentially allergic reactions to the first dose.
https://jamanetwork.com/journals/ja...m=social&utm_term=072621#.YP7U0j6Ma-8.twitter